300 related articles for article (PubMed ID: 19669798)
1. Regulation of phosphate transport by fibroblast growth factor 23 (FGF23): implications for disorders of phosphate metabolism.
Gattineni J; Baum M
Pediatr Nephrol; 2010 Apr; 25(4):591-601. PubMed ID: 19669798
[TBL] [Abstract][Full Text] [Related]
2. Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway.
Rowe PS
Crit Rev Eukaryot Gene Expr; 2012; 22(1):61-86. PubMed ID: 22339660
[TBL] [Abstract][Full Text] [Related]
3. Nuclear isoforms of fibroblast growth factor 2 are novel inducers of hypophosphatemia via modulation of FGF23 and KLOTHO.
Xiao L; Naganawa T; Lorenzo J; Carpenter TO; Coffin JD; Hurley MM
J Biol Chem; 2010 Jan; 285(4):2834-46. PubMed ID: 19933269
[TBL] [Abstract][Full Text] [Related]
4. Altered renal FGF23-mediated activity involving MAPK and Wnt: effects of the Hyp mutation.
Farrow EG; Summers LJ; Schiavi SC; McCormick JA; Ellison DH; White KE
J Endocrinol; 2010 Oct; 207(1):67-75. PubMed ID: 20675303
[TBL] [Abstract][Full Text] [Related]
5. FGF23 and Associated Disorders of Phosphate Wasting.
Gohil A; Imel EA
Pediatr Endocrinol Rev; 2019 Sep; 17(1):17-34. PubMed ID: 31599133
[TBL] [Abstract][Full Text] [Related]
6. Regulation of renal phosphate transport by FGF23 is mediated by FGFR1 and FGFR4.
Gattineni J; Alphonse P; Zhang Q; Mathews N; Bates CM; Baum M
Am J Physiol Renal Physiol; 2014 Feb; 306(3):F351-8. PubMed ID: 24259513
[TBL] [Abstract][Full Text] [Related]
7. Soluble klotho and autosomal dominant polycystic kidney disease.
Pavik I; Jaeger P; Ebner L; Poster D; Krauer F; Kistler AD; Rentsch K; Andreisek G; Wagner CA; Devuyst O; Wüthrich RP; Schmid C; Serra AL
Clin J Am Soc Nephrol; 2012 Feb; 7(2):248-57. PubMed ID: 22193235
[TBL] [Abstract][Full Text] [Related]
8. FGF23 directly inhibits osteoprogenitor differentiation in Dmp1-knockout mice.
Courbon G; Kentrup D; Thomas JJ; Wang X; Tsai HH; Spindler J; Von Drasek J; Ndjonko LM; Martinez-Calle M; Lynch S; Hivert L; Wang X; Chang W; Feng JQ; David V; Martin A
JCI Insight; 2023 Dec; 8(24):. PubMed ID: 37943605
[TBL] [Abstract][Full Text] [Related]
9. FGF23 suppresses chondrocyte proliferation in the presence of soluble α-Klotho both in vitro and in vivo.
Kawai M; Kinoshita S; Kimoto A; Hasegawa Y; Miyagawa K; Yamazaki M; Ohata Y; Ozono K; Michigami T
J Biol Chem; 2013 Jan; 288(4):2414-27. PubMed ID: 23235154
[TBL] [Abstract][Full Text] [Related]
10. Regulation of serum 1,25(OH)2 vitamin D3 levels by fibroblast growth factor 23 is mediated by FGF receptors 3 and 4.
Gattineni J; Twombley K; Goetz R; Mohammadi M; Baum M
Am J Physiol Renal Physiol; 2011 Aug; 301(2):F371-7. PubMed ID: 21561999
[TBL] [Abstract][Full Text] [Related]
11. The chicken or the egg: PHEX, FGF23 and SIBLINGs unscrambled.
Rowe PS
Cell Biochem Funct; 2012 Jul; 30(5):355-75. PubMed ID: 22573484
[TBL] [Abstract][Full Text] [Related]
12. Novel Small Molecule Fibroblast Growth Factor 23 Inhibitors Increase Serum Phosphate and Improve Skeletal Abnormalities in
Xiao Z; Liu J; Liu SH; Petridis L; Cai C; Cao L; Wang G; Chin AL; Cleveland JW; Ikedionwu MO; Carrick JD; Smith JC; Quarles LD
Mol Pharmacol; 2021 Jun; 101(6):408-421. PubMed ID: 35339985
[TBL] [Abstract][Full Text] [Related]
13. Determination of FGF23 Levels for the Diagnosis of FGF23-Mediated Hypophosphatemia.
Hartley IR; Gafni RI; Roszko KL; Brown SM; de Castro LF; Saikali A; Ferreira CR; Gahl WA; Pacak K; Blau JE; Boyce AM; Salusky IB; Collins MT; Florenzano P
J Bone Miner Res; 2022 Nov; 37(11):2174-2185. PubMed ID: 36093861
[TBL] [Abstract][Full Text] [Related]
14. X-linked hypophosphatemia, fibroblast growth factor 23 signaling, and craniosynostosis.
Grimbly C; Graf D; Ward LM; Alexander RT
Exp Biol Med (Maywood); 2023 Nov; 248(22):2175-2182. PubMed ID: 38230523
[TBL] [Abstract][Full Text] [Related]
15. Hypophosphatemia in acute liver failure of a broad range of etiologies is associated with phosphaturia without kidney damage or phosphatonin elevation.
Zechner C; Adams-Huet B; Gregory B; Neyra JA; Rule JA; Li X; Rakela J; Moe OW; Lee WM;
Transl Res; 2021 Dec; 238():1-11. PubMed ID: 34298149
[TBL] [Abstract][Full Text] [Related]
16. FGF23-related hypophosphatemia in a patient with small cell lung cancer: a case report and literature review.
Kato H; Kimura S; Taguchi M; Sunouchi T; Hoshino Y; Hidaka N; Edvige Foligno N; Koga M; Manaka K; Tamiya H; Kawakami M; Kage H; Yasunaga Y; Nangaku M; Makita N; Ito N
Endocr J; 2023 Oct; 70(10):1005-1013. PubMed ID: 37468265
[TBL] [Abstract][Full Text] [Related]
17. Serum MEPE-ASARM-peptides are elevated in X-linked rickets (HYP): implications for phosphaturia and rickets.
Bresler D; Bruder J; Mohnike K; Fraser WD; Rowe PS
J Endocrinol; 2004 Dec; 183(3):R1-9. PubMed ID: 15590969
[TBL] [Abstract][Full Text] [Related]
18. A computationally identified compound antagonizes excess FGF-23 signaling in renal tubules and a mouse model of hypophosphatemia.
Xiao Z; Riccardi D; Velazquez HA; Chin AL; Yates CR; Carrick JD; Smith JC; Baudry J; Quarles LD
Sci Signal; 2016 Nov; 9(455):ra113. PubMed ID: 27879395
[TBL] [Abstract][Full Text] [Related]
19. Hypophosphatemic rickets.
Jagtap VS; Sarathi V; Lila AR; Bandgar T; Menon P; Shah NS
Indian J Endocrinol Metab; 2012 Mar; 16(2):177-82. PubMed ID: 22470852
[TBL] [Abstract][Full Text] [Related]
20. Latin-American consensus on the transition into adult life of patients with X-linked hypophosphatemia.
Kastelic MS; Roman-González A; De Paula Colares Neto G; De Paula FJA; Reza-Albarrán AA; Morales LR; Tormo S; Meza-Martínez AI
Endocrine; 2024 Apr; 84(1):76-91. PubMed ID: 38117452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
